1. Academic Validation
  2. Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells

  • bioRxiv. 2025 Sep 30:2025.09.30.679484. doi: 10.1101/2025.09.30.679484.
Sneh Koul 1 2 Minjung Kwon 1 Poulami Tapadar 1 Yangyang Dai 1 Tulip Nandu 1 2 Dan Huang 1 3 Cristel V Camacho 1 3 W Lee Kraus 1 3
Affiliations

Affiliations

  • 1 Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 2 Computational Core Facility, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 3 Division of Basic Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Abstract

Breast cancers are molecularly heterogeneous, with subtype-specific differences in transcriptional programs, chromatin architecture, and therapeutic responses. While PARP1 has been extensively studied in the context of DNA repair, emerging evidence implicates its catalytic activity in a broader set of cellular processes, including the regulation of gene expression. Here, we employed an NAD analog-sensitive PARP1 (asPARP1) chemical genetics approach combined with mass spectrometry to map the ADP-ribosylated proteome across six human breast Cancer cell lines representing luminal and basal/triple negative subtypes. We identified thousands of PARP1 substrates and hundreds of Glu/Asp ADPRylation sites, revealing both shared and subtype-specific modifications in cell lines maintained under basal growth conditions. Luminal-specific substrates were enriched in chromatin and transcriptional regulators, whereas basal-specific substrates were preferentially linked to translation and RNA processing, highlighting lineage-dependent PARP1 activity. Transcription factors emerged as major substrates, with TFAP2A serving as a proof-of-concept; it is selectively ADPRylated in luminal cells and inhibition of PARP1-mediated ADPRylation modulates its promoter occupancy in a subtype-specific manner. Our data provide a new resource for studying subtype-specific PARP1-mediated ADPRylation in breast Cancer cells. Collectively, our findings expand the conceptual framework for PARP1 function beyond DNA repair, offering mechanistic insights into subtype-specific gene regulation and potential determinants of PARP Inhibitor sensitivity in breast Cancer.

Keywords

ADP-ribosylation (ADPRylation); Breast cancer; Cell growth; Chromatin remodeling complex; Gene regulation; Histone; Histone modifying enzymes; PARP1; Transcription; Transcription factor.

Figures
Products